Japanese drug firm Yamanouchi Pharmaceutical has begun clinical development in Japan of YM454, the company's version of an ultrasound contrast agent licensed from ImaRx Pharmaceutical of Tucson. Yamanouchi has Asian marketing rights for the agent, which
Japanese drug firm Yamanouchi Pharmaceutical has begun clinical development in Japan of YM454, the company's version of an ultrasound contrast agent licensed from ImaRx Pharmaceutical of Tucson. Yamanouchi has Asian marketing rights for the agent, which ImaRx is co-developing in the U.S. with Du Pont Pharmaceutical under the name DMP115.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.